Core Viewpoint - The TransMedics Group, Inc. is facing a class action lawsuit alleging violations of the Securities Exchange Act of 1934, with claims of misconduct including fraudulent practices and safety issues [1][3][4]. Group 1: Class Action Lawsuit Details - The class action lawsuit is titled Jewik v. TransMedics Group, Inc., and covers purchasers of TransMedics securities from February 28, 2023, to January 10, 2025 [1]. - Investors have until April 15, 2025, to seek appointment as lead plaintiff in the lawsuit [1]. - The lawsuit alleges that TransMedics engaged in kickbacks, fraudulent overbilling, and coercive tactics to generate revenue [3]. Group 2: Allegations Against TransMedics - Specific allegations include unsafe practices and a lack of safety oversight, which increased regulatory scrutiny risks [3]. - A letter from U.S. Representative Paul Gosar on February 21, 2024, accused TransMedics of misconduct, leading to a decline in stock price following its public disclosure [4]. - A report from Scorpion Capital on January 10, 2025, further accused TransMedics of overbilling and providing rejected organs to patients, resulting in additional stock price declines [5]. Group 3: Legal Process and Firm Background - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased TransMedics securities during the class period to seek lead plaintiff status [6]. - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud cases, having recovered $6.6 billion for investors in related class action cases [7].

NEW YORK, March 4, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in TransMedics Group, Inc. ("TransMedics" or the "Company") (NASDAQ: TMDX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of TransMedics investors who were adversely affected by alleged securities fraud between February 28, 2023 and January 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/transmedics-gro ...

Company Overview - TransMedics' stock has shown a rebound in recent months, supported by stronger transplant volumes and reduced competition concerns [1] - Despite the rebound, the share price remains low relative to the company's guidance, indicating potential overvaluation of long-term targets [1] Investment Strategy - Narweena, an asset manager led by Richard Durant, focuses on identifying market dislocations due to misinterpretations of long-term business prospects [1] - The firm aims for excess risk-adjusted returns by targeting businesses with secular growth opportunities in markets with high entry barriers [1] - Narweena's investment approach emphasizes company and industry fundamentals to uncover unique insights, with a preference for smaller cap stocks [1] Market Dynamics - An aging population with low growth and stagnating productivity is expected to create new investment opportunities, differing from past trends [1] - Many industries may experience stagnation or secular decline, which could paradoxically enhance business performance due to reduced competition [1] - The economy is increasingly influenced by asset-light businesses, leading to a declining need for infrastructure investments [1] - A large pool of capital is pursuing a limited set of investment opportunities, resulting in rising asset prices and compressed risk premiums over time [1]

NEW YORK, March 3, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of TransMedics Group, Inc. (NASDAQ: TMDX).Shareholders who purchased shares of TMDX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/transmedics-group-inc-loss-submission-form-2/?id=132977&from=4 CLASS PERIOD: Febr ...

Core Viewpoint - A securities class action lawsuit has been filed against TransMedics Group, Inc. for alleged misconduct during the class period from February 28, 2023, to January 10, 2025, with a lead plaintiff deadline set for April 15, 2025 [1]. Allegations Against TransMedics - The complaint alleges that TransMedics engaged in unethical practices, including the use of kickbacks, fraudulent overbilling, and coercive tactics to generate business and revenue [3]. - It is claimed that TransMedics engaged in unsafe practices, concealed safety issues, and lacked proper safety oversight, which increased the company's regulatory risk [3]. Lead Plaintiff Process - Investors in TransMedics have until April 15, 2025, to seek appointment as a lead plaintiff representative, which involves directing the litigation on behalf of all class members [4]. - The lead plaintiff is typically the investor or small group of investors with the largest financial interest in the case [4].

Core Viewpoint - A class action lawsuit has been filed against TransMedics Group, Inc. for alleged violations of securities laws, claiming the company made false and misleading statements regarding its business practices and safety issues [1][4]. Group 1: Lawsuit Details - The lawsuit pertains to securities purchased between February 28, 2023, and January 10, 2025, and investors are encouraged to contact the Schall Law Firm before April 15, 2025, to participate [2]. - The complaint alleges that TransMedics generated revenue through kickbacks, overbilling, and coercive tactics, while concealing safety issues and engaging in unsafe practices [4]. Group 2: Investor Representation - The class in this case has not yet been certified, meaning that until certification occurs, investors are not represented by an attorney [3]. - Investors who suffered losses are invited to join the case to recover their damages [4]. Group 3: Law Firm Information - The Schall Law Firm specializes in securities class action lawsuits and represents investors globally [5]. - Contact information for the Schall Law Firm is provided for investors seeking to discuss their rights [6].

Core Insights - TransMedics Group, Inc. (TMDX) reported fourth-quarter 2024 earnings per share (EPS) of 19 cents, exceeding the Zacks Consensus Estimate of 18 cents by 5.6% and up from 12 cents in the same period last year [1] - The company achieved revenues of $121.6 million, reflecting a year-over-year increase of 49.8% and surpassing the Zacks Consensus Estimate by 10.2% [2] Financial Performance - For the full year 2024, TMDX recorded total sales of $441.5 million, an increase of 83% compared to 2023, with an EPS of $1.01 compared to a loss of 77 cents in 2023 [9] - Gross profit for the fourth quarter improved by 50.3% to $72 million, with a gross margin of 59.2%, slightly up from 59% in the fourth quarter of 2023 [10] - Operating income totaled $8.6 million, compared to $2.6 million in the year-ago period [12] Revenue Breakdown - Net product revenues, which include sales of OCS Perfusion Sets, OCS Solutions, and OCS Consoles, reached $74.9 million, up 44.5% year over year [5] - Service revenues, generated from logistics services supporting transplant programs, improved by 59.3% year over year to $46.7 million during the fourth quarter [8] Operational Highlights - TransMedics has three FDA-approved OCS products for heart, lung, and liver transplantations, representing the only FDA-approved portable, multi-organ, warm perfusion technology platform [4] - The company operates a National OCS Program, providing outsourced organ retrieval and management services, enhancing the efficiency of donor organ procurement [5][6] Market Reaction - Following the strong quarterly performance, TMDX shares rose by 6.9% in after-hours trading on February 27, although the shares have declined by 56.8% over the past six months [3] Future Guidance - For 2025, TransMedics expects revenues to be in the range of $530-$552 million, indicating a growth of 20-25% from 2024 levels, with the Zacks Consensus Estimate at $523.4 million [14]

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $121.6 million, representing approximately 50% growth year-over-year and 12% sequential growth from Q3 2024 [17][40] - Full year 2024 total revenue reached $441.5 million, representing approximately 83% growth over full year 2023 [19][49] - Overall gross margin for Q4 improved to 59%, up from 56% in Q3 2024 [18] - Operating profit for Q4 was $8.6 million, representing approximately 7.1% of total revenue, up from $3.9 million or 4% of total revenue in Q3 2024 [18][47] - Full year gross margin was 59.4%, down from 63.8% in 2023 due to a higher contribution of service revenue [20][52] Business Line Data and Key Metrics Changes - TransMedics transplant logistics service revenue for Q4 was $21.7 million, up from $9.2 million in Q4 2023 and up from $20.1 million in Q3 2024, representing approximately 8% sequential growth [18][40] - Product revenue for Q4 increased to $74.9 million, reflecting a 44.5% year-over-year growth [40] - Service revenue reached $46.7 million, growing 59.3% year-over-year [41] Market Data and Key Metrics Changes - U.S. revenue grew 11% sequentially to $117 million, while OUS revenue grew approximately 51% sequentially to $4 million [17] - For the full year 2024, U.S. revenue grew to $422 million, representing approximately 91% growth over the full year 2023 [19] - Overall U.S. liver transplant volume grew 9% over 2023 to 10,393 [23] Company Strategy and Development Direction - The company aims to expand the utilization of available donor organs for transplantation while delivering the best possible clinical outcomes [8] - Future growth will be driven by the launch of next-gen heart and lung clinical programs targeted for H2 2025 [27][33] - The company plans to strategically invest in business infrastructure to ensure scalability while maintaining quality and reducing supply chain risks [34] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory for 2025, expecting revenue guidance between $530 million and $552 million, representing a 20% to 25% growth over 2024 [36][55] - Management acknowledged operational challenges, including unexpected aircraft maintenance impacting availability and variability in organ transplantation volume [35] - The company remains committed to its mission of expanding access and improving clinical outcomes for patients in need of organ transplants [60] Other Important Information - The company conducted an independent investigation regarding allegations raised in a short report, which found no evidence of fraud or misconduct [10][12] - The company reported a significant step towards sustained financial strength with positive cash flow from operating activities for the first time in 2024, generating $48.8 million compared to a $13 million outflow in 2023 [48][53] Q&A Session Summary Question: How should we think about the quarter-to-quarter cadence implied in your guide? - Management does not issue quarter-to-quarter guidance but acknowledges variability in the transplant market, particularly in Q3 and Q4 due to seasonal factors [64][65] Question: Should we assume liver will continue to drive the majority of growth? - Management believes liver will continue to lead growth until contributions from heart and lung clinical programs become significant [68] Question: What is the confidence level regarding high-volume customers in 2025? - Management has not seen any attrition among high-volume customers and remains confident in their customer base [72] Question: How does the New York Times article on organ allocation impact the business? - Management does not foresee a meaningful impact on business from the article and emphasizes the need for public education on organ transplant challenges [83] Question: What are the expectations for R&D spending growth in 2025? - Management expects to continue strong investment in R&D while achieving modest gains in operating leverage [117]

TransMedics Group, Inc. (NASDAQ:TMDX) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Laine Morgan - Gilmartin Group, Investor Relations Waleed Hassanein - President and Chief Executive Officer Gerardo Hernandez - Chief Financial Officer Conference Call Participants Allen Gong - JPMorgan Josh Jennings - TD Cowen Bill Plovanic - Canaccord Suraj Kalia - Oppenheimer Chris Pasquale - Nephron Research Matthew O'Brien - Piper Sandler David Rescott - Baird Mike Matson - Needham & ...

Core Insights - TransMedics reported a revenue of $121.62 million for the quarter ended December 2024, marking a 49.8% increase year-over-year, and an EPS of $0.19 compared to $0.12 in the same quarter last year [1] - The revenue exceeded the Zacks Consensus Estimate of $110.38 million by 10.19%, and the EPS also surpassed the consensus estimate of $0.18 by 5.56% [1] Revenue Breakdown - Geographic Revenues from the United States reached $116.65 million, exceeding the average estimate of $108.16 million, representing a year-over-year increase of 55.1% [4] - Geographic Revenues from all other countries totaled $3.89 million, surpassing the estimated $3 million, reflecting a 10.7% increase year-over-year [4] - OCS Liver net revenue was reported at $88.98 million, significantly above the average estimate of $76.93 million, indicating a year-over-year growth of 64.3% [4] - OCS Heart net revenue was $28.14 million, slightly below the estimated $28.81 million, but still showing a 35.2% increase compared to the previous year [4] - OCS Lung net revenue was $3.42 million, which is below the average estimate of $3.83 million, but represents a 6.8% increase year-over-year [4] Stock Performance - TransMedics shares have returned +12.6% over the past month, contrasting with a -2.2% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]